Cardiology

Neladenoson does not increase exercise capacity for heart failure with preserved ejection fraction

1. In this randomized controlled trial, heart failure with preserved ejection fraction (HFpEF) patients did not have improved exercise capacity with neladenoson versus placebo. 2. There were no changes in activity intensity, NT-proBNP level, high-sensitivity troponin T level, or quality of life with neladenoson. Evidence Rating Level: 1 (Excellent) Study Czytaj więcej…

Cardiology

Quick Take: Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm

Rivaroxaban is a selective direct factor Xa inhibitor that has been associated with improved outcomes in stable patients with chronic atherosclerotic cardiovascular disease and acute coronary syndrome. Nevertheless, its role in the treatment of patients with coronary artery disease (CAD) in addition to heart failure remains unclear. In the COMMANDER Czytaj więcej…

Cardiology

Quick Take: The burden of health conditions for middle-aged and older adults in the United States: disability-adjusted life years

Understanding the burden of health conditions in older adults in the U.S. is essential in addressing the healthcare demands of this patient population. This is of particular importance as the life expectancy in the U.S. continues to advance. In this retrospective cohort study, investigators analyzed data from 1998-2014 that was Czytaj więcej…

heart failure

#VisualAbstract: Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure

1. In this randomized controlled trial, the injection of mesenchymal precursor cells into the myocardium of patients undergoing a Left Ventricular Assist Device (LVAD) implant did not increase successful temporary weaning from device support. 2. Left ventricular ejection fractions (LVEFs) and quality of life scores were similar between groups. Evidence Czytaj więcej…

Cardiology

Mesenchymal precursor cell transplant did not improve weaning from device support in LVAD patients

1. In this randomized controlled trial, the injection of mesenchymal precursor cells into the myocardium of patients undergoing a Left Ventricular Assist Device (LVAD) implant did not increase successful temporary weaning from device support. 2. LV Ejection Fractions (LVEFs) and quality of life scores were similar between groups. Evidence Rating Czytaj więcej…

heart failure

#VisualAbstract: Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure

1. In this randomized controlled trial, patient-centered transitional care services did not improve a composite of clinical outcomes in hospitalized heart failure patients. 2. Patients who received transitional care had improved discharge readiness scores. Evidence Rating Level: 1 (Excellent) Study Rundown: Heart failure (HF) is a leading cause of hospitalizations in Czytaj więcej…

Cardiology

Patient-centered transitional care services unlikely to benefit hospitalized heart failure patients

1. In this randomized controlled trial, patient-centered transitional care services did not improve a composite of clinical outcomes in hospitalized heart failure patients. 2. Patients who received transitional care had improved discharge readiness scores. Evidence Rating Level: 1 (Excellent) Study Rundown: Heart failure (HF) is a leading cause of hospitalizations Czytaj więcej…

90-day postoperative mortality

Symptomatic and non-symptomatic heart failure associated with increased postoperative mortality in non-cardiac elective surgery

1. In this retrospective cohort study, 90-day postoperative mortality after non-cardiac surgeries was higher for patients with symptomatic or non-symptomatic heart failure than patients without. 2. Postoperative mortality increased with decreasing ejection fraction. Evidence Rating Level: 2 (Good) Study Rundown: Heart failure is an important risk factor for postoperative mortality. Czytaj więcej…

Cardiology

Hospital Readmissions Reduction Program associated with increased 30-day post-discharge mortality for heart failure and pneumonia                                                      

1. In this retrospective cohort study, implementation of the Hospital Readmissions Reduction Program (HRRP) was unexpectedly associated with an increase in 30-day post-discharge mortality for heart failure and pneumonia but not for acute myocardial infarction. 2. There was a lack of association between the HRRP implementation and 45-day post-discharge mortality. Czytaj więcej…